CRISPR Therapeutics AG (CRSP) Latest Company News

Oct 19, 2026, 20:05 UTC
CRISPR Therapeutics AG announced that Chief Financial Officer Raju Prasad will step down to pursue external opportunities.
Source:
- globenewswire.com
Oct 16, 2026, 22:51 UTC
CRISPR Therapeutics AG shares fell 4.48% to $49.21 from the prior session's close.
Source:
- zacks.com
Oct 12, 2026, 23:00 UTC
CRISPR Therapeutics AG shares closed at $51.55, down 3.45% from the prior trading day.
Source:
- zacks.com
Oct 8, 2026, 12:30 UTC
CRISPR Therapeutics AG announced that Phase 1b clinical data for its investigational CTX310 therapy will be presented at the American Heart Association, Inc. Scientific Sessions on November 9, 2026.
Source:
- globenewswire.com
Oct 6, 2026, 22:51 UTC
CRISPR Therapeutics AG shares closed at $54, down 5.82% from the previous close.
Source:
- zacks.com
Sep 15, 2026, 21:50 UTC
CRISPR Therapeutics AG (CRSP) shares closed at $51.80, down 2.19% from the previous trading session, underperforming the S&P 500's 0.45% decline.
Source:
- ca.finance.yahoo.com
- zacks.com
Aug 13, 2026, 07:38 UTC
Bank of America Corp DE reduced its stake in CRISPR Therapeutics AG by 10.4% during the first quarter, selling 113,815 shares and retaining 983,072 shares, as disclosed in a recent SEC filing.
Source:
- defenseworld.net
Aug 5, 2026, 14:09 UTC
CRISPR Therapeutics announced that CTX310 demonstrated promising phase 1 results in lipid disorders, with key data updates expected at ESC Congress and in H2 2026.
Source:
- seekingalpha.com
Aug 5, 2026, 14:09 UTC
CRISPR Therapeutics reported that CASGEVY achieved $76 million in Q2 2026 sales, up 151% year-over-year, and is now targeting sickle cell disease and transfusion-dependent beta thalassemia patients as young as 2 years old.
Source:
- seekingalpha.com
Aug 3, 2026, 20:15 UTC
CRISPR Therapeutics reported its financial results for the second quarter ended June 30, 2026, on August 3, 2026.
Source:
Jun 4, 2026, 00:00 UTC
CRISPR Therapeutics AG elected Samarth Kulkarni as Chairman of the Board of Directors and Ali Behbahani, Maria Fardis, H. Edward Fleming Jr., and Simeon J. George as members of the Board of Directors, effective June 4, 2026.

CRSP

CRISPR Therapeutics AG announced that Chief Financial Officer Raju Prasad will step down to pursue external opportunities.

CRISPR Therapeutics AG shares fell 4.48% to $49.21 from the prior session's close.

CRISPR Therapeutics AG shares closed at $51.55, down 3.45% from the prior trading day.

CRISPR Therapeutics AG announced that Phase 1b clinical data for its investigational CTX310 therapy will be presented at the American Heart Association, Inc. Scientific Sessions on November 9, 2026.

CRISPR Therapeutics AG shares closed at $54, down 5.82% from the previous close.

CRISPR Therapeutics AG (CRSP) shares closed at $51.80, down 2.19% from the previous trading session, underperforming the S&P 500's 0.45% decline.

Bank of America Corp DE reduced its stake in CRISPR Therapeutics AG by 10.4% during the first quarter, selling 113,815 shares and retaining 983,072 shares, as disclosed in a recent SEC filing.

CRISPR Therapeutics announced that CTX310 demonstrated promising phase 1 results in lipid disorders, with key data updates expected at ESC Congress and in H2 2026.

CRISPR Therapeutics reported that CASGEVY achieved $76 million in Q2 2026 sales, up 151% year-over-year, and is now targeting sickle cell disease and transfusion-dependent beta thalassemia patients as young as 2 years old.

CRISPR Therapeutics reported its financial results for the second quarter ended June 30, 2026, on August 3, 2026.

CRISPR Therapeutics AG elected Samarth Kulkarni as Chairman of the Board of Directors and Ali Behbahani, Maria Fardis, H. Edward Fleming Jr., and Simeon J. George as members of the Board of Directors, effective June 4, 2026.